Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Piribedil and platelet aggregation.

G Vairo, M A Scafuro, L Lucarelli

    Journal of Medicine
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Outcome Analysis of the Outpatient Pathway for Advanced Kidney Disease (MaReA): Focus on Dependent Patients].

    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
    Same author

    Normal and abnormal appearance of fetal ganglionic eminence on second-trimester three-dimensional ultrasound.

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2023
    Same author

    Bilateral neuroretinitis and membranous lupus nephritis: 2 infrequent manifestations in juvenile lupus.

    Archivos de la Sociedad Espanola de Oftalmologia·2023
    Same author

    CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.

    Blood cancer journal·2017
    Same author

    TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

    Leukemia·2016
    Same author

    PC1, a non-peptide PKR1-preferring antagonist, reduces pain behavior and spinal neuronal sensitization in neuropathic mice.

    Pharmacological research·2014
    Same journal

    Adequate reduction degree of pituitary gonadotropin levels in the clinical management of short-term hormone replacement therapy of women with menopausal symptoms.

    Journal of medicine·2007
    Same journal

    YABA virus induced tumor in men--long term follow-up and possible bio-warfare role.

    Journal of medicine·2007
    Same journal

    Breast cancer in intraductal carcinogen-treated non-human primates.

    Journal of medicine·2007
    Same journal

    Multiple medical problems following agent orange exposure.

    Journal of medicine·2007
    Same journal

    A gastric hiatal hernia may make abdominal pain disappear.

    Journal of medicine·2007
    Same journal

    Gene expression profiles of late colonic Crohn's disease.

    Journal of medicine·2007
    See all related articles

    Piribedil effectively inhibits platelet aggregation induced by adenosine diphosphate (ADP) and thrombin in rabbit platelet-rich plasma (PRP). This finding highlights piribedil

    Area of Science:

    • Pharmacology
    • Hematology
    • Biochemistry

    Background:

    • Platelet aggregation plays a crucial role in thrombosis.
    • Adenosine diphosphate (ADP) and thrombin are key agonists that induce platelet aggregation.
    • Understanding the effects of pharmacological agents on platelet function is vital for cardiovascular research.

    Purpose of the Study:

    • To investigate the in vitro effects of piribedil on platelet aggregation.
    • To determine the concentration-dependent inhibitory activity of piribedil against ADP and thrombin-induced platelet aggregation.

    Main Methods:

    • Platelet-rich plasma (PRP) was isolated from rabbit blood.
    • Platelet aggregation was measured using aggregometry.
    • The effects of varying concentrations of piribedil on ADP- and thrombin-induced aggregation were assessed.

    Related Experiment Videos

    Main Results:

    • Piribedil demonstrated significant inhibition of both ADP- and thrombin-induced platelet aggregation in rabbit PRP.
    • The inhibitory effect was observed at high concentrations of piribedil.

    Conclusions:

    • Piribedil exhibits antiplatelet activity in vitro.
    • High concentrations of piribedil can suppress platelet aggregation pathways stimulated by ADP and thrombin.